Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Merck and AstraZeneca's Lynparza granted conditional approval in China for mCRPC » 06:52
06/24/21
06/24
06:52
06/24/21
06:52
MRK

Merck

$75.59 /

-0.58 (-0.76%)

, AZN

AstraZeneca

$57.98 /

+0.095 (+0.16%)

AstraZeneca (AZN) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

06/11/21 Morgan Stanley
Organon initiated with an Equal Weight at Morgan Stanley
06/10/21 Evercore ISI
Organon initiated with an Outperform at Evercore ISI
06/09/21 JPMorgan
Merck price target lowered to $100 from $105 at JPMorgan
06/07/21 Truist
Merck price target lowered to $93 from $96 at Truist
AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

Hot Stocks
AstraZeneca's Lynparza approved in China to treat mCRPC » 06:27
06/24/21
06/24
06:27
06/24/21
06:27
AZN

AstraZeneca

$57.98 /

+0.095 (+0.16%)

, MRK

Merck

$75.59 /

-0.58 (-0.76%)

AstraZeneca (AZN) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
MRK Merck
$75.59 /

-0.58 (-0.76%)

06/11/21 Morgan Stanley
Organon initiated with an Equal Weight at Morgan Stanley
06/10/21 Evercore ISI
Organon initiated with an Outperform at Evercore ISI
06/09/21 JPMorgan
Merck price target lowered to $100 from $105 at JPMorgan
06/07/21 Truist
Merck price target lowered to $93 from $96 at Truist
MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

MRK Merck
$75.59 /

-0.58 (-0.76%)

AZN AstraZeneca
$57.98 /

+0.095 (+0.16%)

Yesterday
Hot Stocks
AstraZeneca's Orpathys granted conditional approval in China to treat NSCLC » 06:05
06/23/21
06/23
06:05
06/23/21
06:05
AZN

AstraZeneca

$57.89 /

-0.44 (-0.75%)

The company states:…

The company states: "AstraZeneca and HUTCHMED's Orpathys, or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer, or NSCLC, with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. This approval follows a priority review designation by the Center for Drug Evaluation of China's National Medical Products Administration and marks the first global regulatory approval for the oral, potent, and highly selective MET tyrosine kinase inhibitor. The approval by the NMPA was based on positive results from a single-arm Phase II trial conducted in China in patients with NSCLC with this mutation, including patients with the PSC subtype. Orpathys demonstrated robust anti-tumour activity based on an independent review of objective response rate in the trial's primary endpoint and its disease control rate. Continued approval is contingent upon the successful completion of a confirmatory trial in this patient population."

ShowHide Related Items >><<
AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

AZN AstraZeneca
$57.89 /

-0.44 (-0.75%)

Tuesday
Hot Stocks
E.U. grants AstraZeneca/Merck's Koselugo conditional approval for PN treatment » 06:17
06/22/21
06/22
06:17
06/22/21
06:17
AZN

AstraZeneca

$58.33 /

-0.045 (-0.08%)

, MRK

Merck

$76.73 /

+0.09 (+0.12%)

The company states:…

The company states: "AstraZeneca (AZN) and MSD's (MRK) Koselugo, or selumetinib, has been granted conditional approval in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas , or PN, in paediatric patients with neurofibromatosis type 1 aged three years and above. The approval by the European Commission was based on positive results from the SPRINT Stratum 1 Phase II trial sponsored by the National Institute of Health's National Cancer Institute Cancer Therapy Evaluation Program. This trial showed Koselugo reduced the size of inoperable tumours in children, reducing pain and improving quality of life.7,8 This is the first approval of a medicine for NF1 PN in the EU and follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency in April 2021. Safety and efficacy data from the SPRINT Phase II trial with longer follow up will be provided as one of the conditions of approval. The SPRINT Stratum 1 Phase II trial showed Koselugo demonstrated an objective response rate, or ORR, of 66% in paediatric patients with NF1 PN when treated with Koselugo as twice-daily oral monotherapy.8 ORR is defined as the percentage of patients with confirmed complete or partial response, or at least 20% reduction in tumour volume. Results were published in The New England Journal of Medicine. Reference Link

ShowHide Related Items >><<
MRK Merck
$76.73 /

+0.09 (+0.12%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
MRK Merck
$76.73 /

+0.09 (+0.12%)

06/11/21 Morgan Stanley
Organon initiated with an Equal Weight at Morgan Stanley
06/10/21 Evercore ISI
Organon initiated with an Outperform at Evercore ISI
06/09/21 JPMorgan
Merck price target lowered to $100 from $105 at JPMorgan
06/07/21 Truist
Merck price target lowered to $93 from $96 at Truist
MRK Merck
$76.73 /

+0.09 (+0.12%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

MRK Merck
$76.73 /

+0.09 (+0.12%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

MRK Merck
$76.73 /

+0.09 (+0.12%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

MRK Merck
$76.73 /

+0.09 (+0.12%)

AZN AstraZeneca
$58.33 /

-0.045 (-0.08%)

Friday
Hot Stocks
AstraZeneca 'welcomes' Court ruling on supply of COVID-19 vaccine to Europe » 08:11
06/18/21
06/18
08:11
06/18/21
08:11
AZN

AstraZeneca

$58.36 /

-0.065 (-0.11%)

AstraZeneca announced…

AstraZeneca announced that it "welcomed" the ruling by the Court of First Instance in Brussels on supply of its COVID-19 vaccine to Europe. "The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses by 27 September 2021. To date, the Company has supplied more than 70 million doses to the European Union and will substantially exceed 80.2 million doses by the end of June 2021. All other measures sought by the European Commission have been dismissed, and in particular the Court found that the European Commission has no exclusivity or right of priority over all other contracting parties. The judgement also acknowledged that the difficulties experienced by AstraZeneca in this unprecedented situation had a substantial impact on the delay. AstraZeneca now looks forward to renewed collaboration with the European Commission to help combat the pandemic in Europe. The Company remains committed to broad and equitable distribution of the vaccine as laid out in the Advanced Purchase Agreement of August 2020. In fewer than twelve months, AstraZeneca has worked extremely hard to develop an effective vaccine at no profit and is the second-largest supplier to the EU's 27 member states," the company stated.

ShowHide Related Items >><<
AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

AZN AstraZeneca
$58.36 /

-0.065 (-0.11%)

Over a week ago
Recommendations
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS » 13:16
06/17/21
06/17
13:16
06/17/21
13:16
AZN

AstraZeneca

$58.14 /

-0.28 (-0.48%)

UBS analyst Michael…

UBS analyst Michael Leuchten raised the firm's price target on AstraZeneca to 9,200 GBp from 8,000 GBp and keeps a Buy rating on the shares.

ShowHide Related Items >><<
AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

AZN AstraZeneca
$58.14 /

-0.28 (-0.48%)

On The Fly
Wall Street in Fives - Must Read Lists for Tuesday » 16:25
06/15/21
06/15
16:25
06/15/21
16:25
BA

Boeing

$246.55 /

+1.48 (+0.60%)

, EADSY

Airbus

$34.33 /

+0.32 (+0.94%)

, NVAX

Novavax

$187.15 /

-21.05 (-10.11%)

, AZN

AstraZeneca

$58.84 /

+0.09 (+0.15%)

, AAPL

Apple

$129.75 /

-0.74 (-0.57%)

, GOOG

Alphabet

$2,520.68 /

-6.19 (-0.24%)

, GOOGL

Alphabet Class A

$2,428.41 /

-16.59 (-0.68%)

, NTDOY

Nintendo

$73.23 /

-1.05 (-1.41%)

, WPC

W.P. Carey

$77.61 /

-0.03 (-0.04%)

, CR

Crane

$91.81 /

+0.995 (+1.10%)

, ACRS

Aclaris Therapeutics

$17.73 /

-0.005 (-0.03%)

, CDAY

Ceridian

$84.54 /

-4.64 (-5.20%)

, FAST

Fastenal

$51.54 /

-1.19 (-2.26%)

, AMZN

Amazon.com

$3,381.76 /

-0.86 (-0.03%)

, DKNG

DraftKings

$48.51 /

-2.115 (-4.18%)

, DISH

Dish

$40.16 /

+0.135 (+0.34%)

, MSFT

Microsoft

$258.65 /

-1.3 (-0.50%)

, NFLX

Netflix

$492.17 /

-7.43 (-1.49%)

, OCGN

Ocugen

$6.28 /

+0.13 (+2.11%)

, ELAN

Elanco

$34.83 /

+1.33 (+3.97%)

, FOA

Finance of America

$8.85 /

+1.55 (+21.23%)

, SAGE

Sage Therapeutics

$59.00 /

-13.88 (-19.05%)

, VRM

Vroom

$40.01 /

-5.125 (-11.36%)

, SAVE

Spirit Airlines

$33.99 /

+0.035 (+0.10%)

, QD

Qudian

$2.39 /

-0.05 (-2.05%)

, BCOR

Blucora

$18.34 /

+1.37 (+8.07%)

, HLIO

Helios Technologies

$73.85 /

+1.88 (+2.61%)

, BBCP

Concrete Pumping

$8.43 /

-0.11 (-1.29%)

Get caught up quickly on…

ShowHide Related Items >><<
WPC W.P. Carey
$77.61 /

-0.03 (-0.04%)

VRM Vroom
$40.01 /

-5.125 (-11.36%)

SAVE Spirit Airlines
$33.99 /

+0.035 (+0.10%)

SAGE Sage Therapeutics
$59.00 /

-13.88 (-19.05%)

QD Qudian
$2.39 /

-0.05 (-2.05%)

OCGN Ocugen
$6.28 /

+0.13 (+2.11%)

NVAX Novavax
$187.15 /

-21.05 (-10.11%)

NTDOY Nintendo
$73.23 /

-1.05 (-1.41%)

NFLX Netflix
$492.17 /

-7.43 (-1.49%)

MSFT Microsoft
$258.65 /

-1.3 (-0.50%)

HLIO Helios Technologies
$73.85 /

+1.88 (+2.61%)

GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

FOA Finance of America
$8.85 /

+1.55 (+21.23%)

FAST Fastenal
$51.54 /

-1.19 (-2.26%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

EADSY Airbus
$34.33 /

+0.32 (+0.94%)

DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

DISH Dish
$40.16 /

+0.135 (+0.34%)

CR Crane
$91.81 /

+0.995 (+1.10%)

CDAY Ceridian
$84.54 /

-4.64 (-5.20%)

BCOR Blucora
$18.34 /

+1.37 (+8.07%)

BBCP Concrete Pumping
$8.43 /

-0.11 (-1.29%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

ACRS Aclaris Therapeutics
$17.73 /

-0.005 (-0.03%)

AAPL Apple
$129.75 /

-0.74 (-0.57%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

06/15/21 Berenberg
Boeing price target raised to $245 from $215 at Berenberg
06/10/21 Jefferies
Boeing shares could move up 5% on China recertification, says Jefferies
06/09/21 Susquehanna
Boeing estimates lowered on light May deliveries, says Susquehanna
06/03/21 Morgan Stanley
Morgan Stanley says recovery tailwinds can offset new launch headwinds at Boeing
EADSY Airbus
$34.33 /

+0.32 (+0.94%)

06/15/21 Berenberg
Airbus price target raised to EUR 140 from EUR 110 at Berenberg
06/11/21 Credit Suisse
Airbus assumed with an Outperform at Credit Suisse
06/02/21 Barclays
Airbus price target raised to EUR 138 from EUR 113 at Barclays
06/02/21
Fly Intel: Top five analyst upgrades
NVAX Novavax
$187.15 /

-21.05 (-10.11%)

06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
AAPL Apple
$129.75 /

-0.74 (-0.57%)

06/11/21 Argus
Apple underperformance due to sector rotation, not misfires, says Argus
06/08/21 RBC Capital
Fisker initiated with an Outperform at RBC Capital
06/08/21 BofA
Apple App store growth decelerating in Q3 to-date, says BofA
06/08/21 Wedbush
Apple WWDC 'all about iOS 15, new Macs,' says Wedbush
GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

06/16/21 Jefferies
Jefferies adds Amazon.com to Franchise Picks list, removes Alphabet
06/11/21 Tigress Financial
Tigress sees Alphabet shares rising to $3,185 in 12 months
06/02/21 KGI Securities
Alphabet initiated with an Outperform at KGI Securities
05/19/21 JPMorgan
Broadcom continues to win AI chip work at Google, says JPMorgan
GOOGL Alphabet Class A
$2,428.41 /

-16.59 (-0.68%)

06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
NTDOY Nintendo
$73.23 /

-1.05 (-1.41%)

05/21/21 Citi
Nintendo downgraded to Neutral from Buy at Citi
11/06/20 DZ Bank
Nintendo upgraded to Buy from Sell at DZ Bank
09/10/20 Jefferies
Nintendo upgraded to Buy on WFH boost at Jefferies
09/10/20 Jefferies
Nintendo upgraded to Buy from Hold at Jefferies
WPC W.P. Carey
$77.61 /

-0.03 (-0.04%)

06/15/21
Fly Intel: Top five analyst upgrades
06/15/21 JPMorgan
JPMorgan upgrades W.P. Carey on swap out of Broadstone
06/15/21 JPMorgan
W.P. Carey upgraded to Overweight from Neutral at JPMorgan
05/03/21 Evercore ISI
W.P. Carey upgraded to Outperform at Evercore ISI on accelerating acquisitions
CR Crane
$91.81 /

+0.995 (+1.10%)

06/15/21 DA Davidson
Crane upgraded to Buy at DA Davidson following Engineered Materials divestment
06/15/21 DA Davidson
Crane upgraded to Buy from Neutral at DA Davidson
05/05/21 DA Davidson
Crane price target raised to $105 from $85 at DA Davidson
ACRS Aclaris Therapeutics
$17.73 /

-0.005 (-0.03%)

06/16/21 H.C. Wainwright
Aclaris Therapeutics price target raised to $50 from $40 at H.C. Wainwright
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
CDAY Ceridian
$84.54 /

-4.64 (-5.20%)

06/15/21
Fly Intel: Top five analyst downgrades
06/15/21 Needham
Ceridian downgraded to Hold from Buy at Needham
05/28/21 Jefferies
Ceridian price target lowered to $95 from $110 at Jefferies
05/06/21 Mizuho
Ceridian price target raised to $120 from $110 at Mizuho
FAST Fastenal
$51.54 /

-1.19 (-2.26%)

06/15/21 Morgan Stanley
Fastenal downgraded to Underweight from Equal Weight at Morgan Stanley
06/04/21 Raymond James
Fastenal's May ADS down 3.2% off challenging comparison, says Raymond James
05/03/21 Raymond James
Grainger price target raised to $460 from $400 at Raymond James
AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

06/16/21 JPMorgan
JPMorgan values Amazon Prime at $1,000 per year, 8.5 times actual price
06/16/21 Pivotal Research
Dish upgraded to Buy from Hold at Pivotal Research
06/15/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

06/16/21 Susquehanna
DraftKings report referenced allegations prior to acquisition, says Susquehanna
06/16/21 Morgan Stanley
Morgan Stanley says DraftKings opportunity around core U.S. business, not SBTech
06/15/21 Credit Suisse
DraftKings selloff on short report overdone, says Credit Suisse
06/02/21 Morgan Stanley
DraftKings price target lowered to $58 from $63 at Morgan Stanley
DISH Dish
$40.16 /

+0.135 (+0.34%)

06/09/21
Fly Intel: Top five analyst downgrades
06/09/21 JPMorgan
JPMorgan downgrades Dish to sell on wireless execution concerns
06/09/21 JPMorgan
Dish downgraded to Underweight from Neutral at JPMorgan
MSFT Microsoft
$258.65 /

-1.3 (-0.50%)

06/15/21 Oppenheimer
Turtle Beach price target raised to $45 from $40 at Oppenheimer
06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
06/01/21 KGI Securities
Microsoft initiated with an Outperform at KGI Securities
NFLX Netflix
$492.17 /

-7.43 (-1.49%)

06/16/21 JPMorgan
JPMorgan 'incrementally positive' on Netflix into second half content slate
06/01/21 KGI Securities
Netflix initiated with a Neutral at KGI Securities
05/27/21 Stifel
Stifel sees 'minimal impact' to Netflix from Amazon's MGM acquisition
05/27/21 Benchmark
Streaming field 'looking ever less unipolar around Netflix,' says Benchmark
OCGN Ocugen
$6.28 /

+0.13 (+2.11%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
06/10/21 Roth Capital
Ocugen downgraded to Neutral from Buy at Roth Capital
06/10/21 Chardan
Ocugen price target lowered to $4.50 from $8 at Chardan
ELAN Elanco
$34.83 /

+1.33 (+3.97%)

06/15/21 Cleveland Research
Elanco upgraded to Neutral from Underperform at Cleveland Research
05/17/21 Citi
Elanco price target raised to $42 from $39 at Citi
05/11/21 Gabelli
Elanco upgraded to Buy from Hold at Gabelli
05/11/21 Barclays
Elanco upgraded to Equal Weight from Underweight at Barclays
FOA Finance of America
$8.85 /

+1.55 (+21.23%)

06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
04/23/21 Raymond James
First of America initiated with an Outperform at Raymond James
SAGE Sage Therapeutics
$59.00 /

-13.88 (-19.05%)

06/16/21 William Blair
Sage Therapeutics downgraded to Market Perform from Outperform at William Blair
06/16/21 BMO Capital
Sage Therapeutics price target lowered to $73 from $87 at BMO Capital
06/16/21 Citi
Sage Therapeutics downgraded to Neutral from Buy at Citi
06/15/21 Piper Sandler
Street 'unfairly penalizing' Sage depression drug, says Piper Sandler
VRM Vroom
$40.01 /

-5.125 (-11.36%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
SAVE Spirit Airlines
$33.99 /

+0.035 (+0.10%)

06/15/21 Citi
Spirit Airlines upgraded to Buy from Neutral at Citi
06/09/21 MKM Partners
MKM sees 'a lot to like' in Spirit Airlines' valuation
06/09/21 MKM Partners
Spirit Airlines initiated with a Buy at MKM Partners
QD Qudian
$2.39 /

-0.05 (-2.05%)

BCOR Blucora
$18.34 /

+1.37 (+8.07%)

04/01/21 JPMorgan
Blucora assumed with an Overweight at JPMorgan
02/17/21 Barrington
Blucora price target raised to $19 from $16 at Barrington
08/05/20 Barrington
Blucora price target lowered to $15 from $18 at Barrington
HLIO Helios Technologies
$73.85 /

+1.88 (+2.61%)

06/15/21 Baird
Helios Technologies price target raised to $94 from $89 at Baird
05/11/21 Baird
Helios Technologies price target raised to $89 from $84 at Baird
05/11/21 Baird
Helios Technologies updated guidance above previous range, says Baird
03/02/21 Baird
Helios Technologies price target raised to $82 from $72 at Baird
BBCP Concrete Pumping
$8.43 /

-0.11 (-1.29%)

06/15/21 Baird
Concrete Pumping price target raised to $11 from $10 at Baird
04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
01/13/21 B. Riley
Concrete Pumping price target lowered to $6 from $6.75 at B. Riley Securities
01/07/21 B. Riley
Concrete Pumping price target raised to $6.75 from $6.50 at B. Riley Securities
WPC W.P. Carey
$77.61 /

-0.03 (-0.04%)

VRM Vroom
$40.01 /

-5.125 (-11.36%)

SAVE Spirit Airlines
$33.99 /

+0.035 (+0.10%)

SAGE Sage Therapeutics
$59.00 /

-13.88 (-19.05%)

QD Qudian
$2.39 /

-0.05 (-2.05%)

OCGN Ocugen
$6.28 /

+0.13 (+2.11%)

NVAX Novavax
$187.15 /

-21.05 (-10.11%)

NTDOY Nintendo
$73.23 /

-1.05 (-1.41%)

NFLX Netflix
$492.17 /

-7.43 (-1.49%)

MSFT Microsoft
$258.65 /

-1.3 (-0.50%)

HLIO Helios Technologies
$73.85 /

+1.88 (+2.61%)

GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

FAST Fastenal
$51.54 /

-1.19 (-2.26%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

EADSY Airbus
$34.33 /

+0.32 (+0.94%)

DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

DISH Dish
$40.16 /

+0.135 (+0.34%)

CR Crane
$91.81 /

+0.995 (+1.10%)

CDAY Ceridian
$84.54 /

-4.64 (-5.20%)

BCOR Blucora
$18.34 /

+1.37 (+8.07%)

BBCP Concrete Pumping
$8.43 /

-0.11 (-1.29%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

ACRS Aclaris Therapeutics
$17.73 /

-0.005 (-0.03%)

AAPL Apple
$129.75 /

-0.74 (-0.57%)

  • 10
    Jun
  • 08
    Jun
  • 20
    Jan
  • 07
    Dec
  • 01
    Dec
  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 26
    Aug
  • 18
    Jun
  • 19
    Jun
VRM Vroom
$40.01 /

-5.125 (-11.36%)

SAVE Spirit Airlines
$33.99 /

+0.035 (+0.10%)

OCGN Ocugen
$6.28 /

+0.13 (+2.11%)

NVAX Novavax
$187.15 /

-21.05 (-10.11%)

NTDOY Nintendo
$73.23 /

-1.05 (-1.41%)

NFLX Netflix
$492.17 /

-7.43 (-1.49%)

MSFT Microsoft
$258.65 /

-1.3 (-0.50%)

GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

EADSY Airbus
$34.33 /

+0.32 (+0.94%)

DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

DISH Dish
$40.16 /

+0.135 (+0.34%)

CR Crane
$91.81 /

+0.995 (+1.10%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

AAPL Apple
$129.75 /

-0.74 (-0.57%)

VRM Vroom
$40.01 /

-5.125 (-11.36%)

NVAX Novavax
$187.15 /

-21.05 (-10.11%)

NTDOY Nintendo
$73.23 /

-1.05 (-1.41%)

NFLX Netflix
$492.17 /

-7.43 (-1.49%)

HLIO Helios Technologies
$73.85 /

+1.88 (+2.61%)

GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

FAST Fastenal
$51.54 /

-1.19 (-2.26%)

ELAN Elanco
$34.83 /

+1.33 (+3.97%)

DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

DISH Dish
$40.16 /

+0.135 (+0.34%)

CR Crane
$91.81 /

+0.995 (+1.10%)

CDAY Ceridian
$84.54 /

-4.64 (-5.20%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

ACRS Aclaris Therapeutics
$17.73 /

-0.005 (-0.03%)

AAPL Apple
$129.75 /

-0.74 (-0.57%)

VRM Vroom
$40.01 /

-5.125 (-11.36%)

SAVE Spirit Airlines
$33.99 /

+0.035 (+0.10%)

QD Qudian
$2.39 /

-0.05 (-2.05%)

OCGN Ocugen
$6.28 /

+0.13 (+2.11%)

NVAX Novavax
$187.15 /

-21.05 (-10.11%)

NFLX Netflix
$492.17 /

-7.43 (-1.49%)

MSFT Microsoft
$258.65 /

-1.3 (-0.50%)

GOOGL Alphabet Class A
$2,428.41 /

-16.59 (-0.68%)

GOOG Alphabet
$2,520.68 /

-6.19 (-0.24%)

FOA Finance of America
$8.85 /

+1.55 (+21.23%)

DKNG DraftKings
$48.51 /

-2.115 (-4.18%)

DISH Dish
$40.16 /

+0.135 (+0.34%)

BA Boeing
$246.55 /

+1.48 (+0.60%)

AZN AstraZeneca
$58.84 /

+0.09 (+0.15%)

AMZN Amazon.com
$3,381.76 /

-0.86 (-0.03%)

AAPL Apple
$129.75 /

-0.74 (-0.57%)

On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:06
06/15/21
06/15
12:06
06/15/21
12:06
BA

Boeing

$245.71 /

+0.64 (+0.26%)

, EADSY

Airbus

$34.01 /

-0.02 (-0.06%)

, NVAX

Novavax

$189.20 /

-19 (-9.13%)

, AZN

AstraZeneca

$58.62 /

-0.13 (-0.22%)

, CLSD

Clearside Biomedical

$3.84 /

+0.8 (+26.32%)

, DCRC

Decarbonization Plus Acquisition III

$10.72 /

-1.31 (-10.89%)

, WPC

W.P. Carey

$77.50 /

-0.14 (-0.18%)

, CR

Crane

$91.42 /

+0.61 (+0.67%)

, ACRS

Aclaris Therapeutics

$17.59 /

-0.14 (-0.79%)

, CDAY

Ceridian

$85.53 /

-3.65 (-4.09%)

, FAST

Fastenal

$51.70 /

-1.03 (-1.95%)

, AMZN

Amazon.com

$3,371.43 /

-11.19 (-0.33%)

, DKNG

DraftKings

$48.28 /

-2.34 (-4.62%)

, DISH

Dish

$39.69 /

-0.335 (-0.84%)

, MSFT

Microsoft

$259.24 /

-0.71 (-0.27%)

, NFLX

Netflix

$494.25 /

-5.35 (-1.07%)

, OCGN

Ocugen

$6.59 /

+0.44 (+7.15%)

, ELAN

Elanco

$35.23 /

+1.73 (+5.16%)

, FOA

Finance of America

$8.83 /

+1.53 (+20.96%)

, SAGE

Sage Therapeutics

$60.33 /

-12.55 (-17.22%)

, VRM

Vroom

$40.55 /

-4.58 (-10.15%)

, SAVE

Spirit Airlines

$33.83 /

-0.125 (-0.37%)

, QD

Qudian

$2.25 /

-0.19 (-7.79%)

, BCOR

Blucora

$18.37 /

+1.4 (+8.25%)

, HLIO

Helios Technologies

$72.61 /

+0.64 (+0.89%)

, BBCP

Concrete Pumping

$8.44 /

-0.1 (-1.17%)

Get caught up quickly on…

ShowHide Related Items >><<
WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FOA Finance of America
$8.83 /

+1.53 (+20.96%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BCOR Blucora
$18.37 /

+1.4 (+8.25%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

06/15/21 Berenberg
Boeing price target raised to $245 from $215 at Berenberg
06/10/21 Jefferies
Boeing shares could move up 5% on China recertification, says Jefferies
06/09/21 Susquehanna
Boeing estimates lowered on light May deliveries, says Susquehanna
06/03/21 Morgan Stanley
Morgan Stanley says recovery tailwinds can offset new launch headwinds at Boeing
EADSY Airbus
$34.01 /

-0.02 (-0.06%)

06/15/21 Berenberg
Airbus price target raised to EUR 140 from EUR 110 at Berenberg
06/11/21 Credit Suisse
Airbus assumed with an Outperform at Credit Suisse
06/02/21 Barclays
Airbus price target raised to EUR 138 from EUR 113 at Barclays
06/02/21
Fly Intel: Top five analyst upgrades
NVAX Novavax
$189.20 /

-19 (-9.13%)

06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

06/15/21 Roth Capital
Clearside reported 'impressive' data in wet AMD, says Roth Capital
06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

06/15/21
Fly Intel: Top five analyst upgrades
06/15/21 JPMorgan
JPMorgan upgrades W.P. Carey on swap out of Broadstone
06/15/21 JPMorgan
W.P. Carey upgraded to Overweight from Neutral at JPMorgan
05/03/21 Evercore ISI
W.P. Carey upgraded to Outperform at Evercore ISI on accelerating acquisitions
CR Crane
$91.42 /

+0.61 (+0.67%)

06/15/21 DA Davidson
Crane upgraded to Buy at DA Davidson following Engineered Materials divestment
06/15/21 DA Davidson
Crane upgraded to Buy from Neutral at DA Davidson
05/05/21 DA Davidson
Crane price target raised to $105 from $85 at DA Davidson
ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

06/15/21
Fly Intel: Top five analyst downgrades
06/15/21 Needham
Ceridian downgraded to Hold from Buy at Needham
05/28/21 Jefferies
Ceridian price target lowered to $95 from $110 at Jefferies
05/06/21 Mizuho
Ceridian price target raised to $120 from $110 at Mizuho
FAST Fastenal
$51.70 /

-1.03 (-1.95%)

06/15/21 Morgan Stanley
Fastenal downgraded to Underweight from Equal Weight at Morgan Stanley
06/04/21 Raymond James
Fastenal's May ADS down 3.2% off challenging comparison, says Raymond James
05/03/21 Raymond James
Grainger price target raised to $460 from $400 at Raymond James
AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

06/15/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
06/14/21 Evercore ISI
Synchrony price target raised to $56 from $49 at Evercore ISI
06/08/21 Piper Sandler
New Amazon offering targets Hims & Hers and others, says Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

06/15/21 Credit Suisse
DraftKings selloff on short report overdone, says Credit Suisse
06/02/21 Morgan Stanley
DraftKings price target lowered to $58 from $63 at Morgan Stanley
05/24/21 Argus
DraftKings price target lowered to $60 from $78 at Argus
05/12/21
Fly Intel: Top five analyst upgrades
DISH Dish
$39.69 /

-0.335 (-0.84%)

06/09/21
Fly Intel: Top five analyst downgrades
06/09/21 JPMorgan
JPMorgan downgrades Dish to sell on wireless execution concerns
06/09/21 JPMorgan
Dish downgraded to Underweight from Neutral at JPMorgan
05/24/21 HSBC
Dish price target raised to $40 from $26 at HSBC
MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

06/15/21 Oppenheimer
Turtle Beach price target raised to $45 from $40 at Oppenheimer
06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
06/01/21 KGI Securities
Microsoft initiated with an Outperform at KGI Securities
NFLX Netflix
$494.25 /

-5.35 (-1.07%)

06/01/21 KGI Securities
Netflix initiated with a Neutral at KGI Securities
05/27/21 Stifel
Stifel sees 'minimal impact' to Netflix from Amazon's MGM acquisition
05/27/21 Benchmark
Streaming field 'looking ever less unipolar around Netflix,' says Benchmark
05/26/21 Piper Sandler
Amazon deal to buy MGM Studios 'looks sensible,' says Piper Sandler
OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
06/10/21 Roth Capital
Ocugen downgraded to Neutral from Buy at Roth Capital
06/10/21 Chardan
Ocugen price target lowered to $4.50 from $8 at Chardan
ELAN Elanco
$35.23 /

+1.73 (+5.16%)

06/15/21 Cleveland Research
Elanco upgraded to Neutral from Underperform at Cleveland Research
05/17/21 Citi
Elanco price target raised to $42 from $39 at Citi
05/11/21 Gabelli
Elanco upgraded to Buy from Hold at Gabelli
05/11/21 Barclays
Elanco upgraded to Equal Weight from Underweight at Barclays
FOA Finance of America
$8.83 /

+1.53 (+20.96%)

06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
04/23/21 Raymond James
First of America initiated with an Outperform at Raymond James
SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

06/15/21 Stifel
Sage, Biogen data support FDA approval in depression, says Stifel
06/15/21 Piper Sandler
Sage selloff on zuranolone data an overreaction, says Piper Sandler
05/05/21 Mizuho
Sage Therapeutics price target lowered to $77 from $81 at Mizuho
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
VRM Vroom
$40.55 /

-4.58 (-10.15%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

06/15/21 Citi
Spirit Airlines upgraded to Buy from Neutral at Citi
06/09/21 MKM Partners
MKM sees 'a lot to like' in Spirit Airlines' valuation
06/09/21 MKM Partners
Spirit Airlines initiated with a Buy at MKM Partners
QD Qudian
$2.25 /

-0.19 (-7.79%)

06/16/20 China Renaissance
China Renaissance ups LexinFintech to Buy, raises Fintech sector to Overweight
BCOR Blucora
$18.37 /

+1.4 (+8.25%)

04/01/21 JPMorgan
Blucora assumed with an Overweight at JPMorgan
02/17/21 Barrington
Blucora price target raised to $19 from $16 at Barrington
08/05/20 Barrington
Blucora price target lowered to $15 from $18 at Barrington
HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

05/11/21 Baird
Helios Technologies price target raised to $89 from $84 at Baird
05/11/21 Baird
Helios Technologies updated guidance above previous range, says Baird
03/02/21 Baird
Helios Technologies price target raised to $82 from $72 at Baird
10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

06/15/21 Baird
Concrete Pumping price target raised to $11 from $10 at Baird
04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
01/13/21 B. Riley
Concrete Pumping price target lowered to $6 from $6.75 at B. Riley Securities
01/07/21 B. Riley
Concrete Pumping price target raised to $6.75 from $6.50 at B. Riley Securities
WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BCOR Blucora
$18.37 /

+1.4 (+8.25%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

  • 10
    Jun
  • 08
    Jun
  • 20
    Jan
  • 07
    Dec
  • 01
    Dec
  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 26
    Aug
  • 18
    Jun
  • 19
    Jun
VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

FOA Finance of America
$8.83 /

+1.53 (+20.96%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

Hot Stocks
AstraZeneca: Covid-19 vaccine effective against Delta variant » 06:07
06/15/21
06/15
06:07
06/15/21
06:07
AZN

AstraZeneca

$58.75 /

-0.02 (-0.03%)

New data from Public…

New data from Public Health England demonstrated COVID-19 Vaccine AstraZeneca offers high levels of protection against the Delta variant, AstraZeneca said in a statement. Real world data from PHE, published as a pre-print, demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalization due to the Delta variant and showed no deaths among those vaccinated. The vaccine also showed a high level of effectiveness against the Alpha variant with an 86% reduction of hospitalizations and no deaths reported. The data suggest that vaccine effectiveness against milder symptomatic disease, although significant, was lower. Vaccine effectiveness against symptomatic disease was 74% against the Alpha variant and 64% against the Delta variant. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "This real world evidence shows that COVID-19 Vaccine AstraZeneca provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. The data show that the vaccine will continue to have a significant impact around the world given that it continues to account for the overwhelming majority of supplies to India and the COVAX facility." Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

Hot Stocks
AstraZeneca: Storm Chaser trial did not meet primary endpoint » 06:05
06/15/21
06/15
06:05
06/15/21
06:05
AZN

AstraZeneca

$58.75 /

-0.02 (-0.03%)

AstraZeneca announced…

AstraZeneca announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo. Trial participants were unvaccinated adults 18 years and over with confirmed exposure to a person with a case of the SARS-CoV-2 virus within the past eight days. In the overall trial population, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to placebo, which was not statistically significant. Myron J. Levin, MD, Professor of Pediatrics and Medicine, University of Colorado School of Medicine, US, and principal investigator on the trial, said: "The results of STORM CHASER suggest that AZD7442 may be useful in preventing symptomatic COVID-19 in individuals not already infected. The PROVENT trial will give us more clarity in this patient population. While COVID-19 vaccination efforts have been successful, there is still a significant need for prevention and treatment options for certain populations, including those unable to be vaccinated or those who may have an inadequate response to vaccination." Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

AZN AstraZeneca
$58.75 /

-0.02 (-0.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.